Judit Harsing
Overview
Explore the profile of Judit Harsing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuzmanovszki D, Kiss N, Toth B, Toth V, Szakonyi J, Lorincz K, et al.
J Clin Med
. 2023 Sep;
12(18).
PMID: 37762907
Background: The systemic treatment of advanced cutaneous squamous cell carcinoma (cSCC) has seen significant developments in recent years. The anti-PD1 inhibitor cemiplimab has demonstrated efficacy in clinical trials, but real-world...
2.
Banvolgyi A, Avci P, Kiss N, Meznerics F, Jobbagy A, Fesus L, et al.
J Clin Tuberc Other Mycobact Dis
. 2023 May;
31:100370.
PMID: 37122612
Tuberculosis remains a global health concern, as the increasing levels of urban poverty, higher number of immunodeficient patients and the development of drug resistance threaten the overall efforts made to...
3.
Kuzmanovszki D, Kiss N, Toth B, Kerner T, Toth V, Szakonyi J, et al.
Biomedicines
. 2022 Jul;
10(7).
PMID: 35885042
Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has...
4.
Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
Toth B, Kiss N, Harsing J, Karpati S, Csomor J, Bodor C, et al.
Virchows Arch
. 2020 May;
477(5):749-753.
PMID: 32372223
Langerhans cell histiocytosis (LCH) is characterized by mutations of the RAS-RAF-MAPK signaling pathway. We analyzed MAP2K1, NRAS and KIT mutation incidence in skin lesions of BRAF wild-type (wt) LCH patients....
5.
Medvecz M, Kiss N, Harsing J, Kuroli E, Hegede G, Csomor J, et al.
Acta Dermatovenerol Croat
. 2019 Sep;
27(3):202-204.
PMID: 31542070
Dear Editor, Lymphomatoid papulosis (LP) is a chronic, recurrent, usually self-limited papulonecrotic or papulonodular skin disease, which belongs to the group of primary cutaneous CD30+ lymphoproliferative disorders (1). Three main...
6.
Kiss N, Haluszka D, Lorincz K, Kuroli E, Harsing J, Mayer B, et al.
Arch Dermatol Res
. 2018 May;
310(5):463-473.
PMID: 29725758
Ehlers-Danlos syndrome (EDS) is the name for a heterogenous group of rare genetic connective tissue disorders with an overall incidence of 1 in 5000. The histological characteristics of EDS have...
7.
Marschalko M, Gyongyosi N, Noll J, Karolyi Z, Wikonkal N, Harsing J, et al.
J Cutan Pathol
. 2016 Jul;
43(11):963-973.
PMID: 27461449
Lymphomatoid papulosis (LyP) belongs to CD30+ lymphoproliferative disorders with indolent clinical course. Classic histological subtypes, A, B and C are characterized by the CD4+ phenotype, while CD8+ variants, most commonly...
8.
Hollo P, Jokai H, Harsing J, Soos G, Karpati S, Nemeth K
J Am Acad Dermatol
. 2016 Jun;
75(1):212-3.
PMID: 27317517
No abstract available.
9.
Fabian M, Toth V, Somlai B, Harsing J, Kuroli E, Rencz F, et al.
Pathol Oncol Res
. 2015 Jul;
21(4):1265-71.
PMID: 26177701
Pregnancy associated melanoma (PAM) by definition appears during pregnancy or within 1 year after delivery. In this retrospective study we analysed the pathological characteristics and survival rate of PAM and...
10.
Marosvari D, Teglasi V, Csala I, Marschalko M, Bodor C, Timar B, et al.
Pathol Oncol Res
. 2015 Feb;
21(3):821-5.
PMID: 25698383
Mycosis fungoides (MF) is a common, indolent primary cutaneous T-cell lymphoma (CTCL), with rare, more aggressive variants, such as folliculotropic MF (FMF). A minority of the MF cases may undergo...